Tritace®/Triatec®/Delix®/Altace® (ramipril)

Tritace® (ramipril) is an angiotensin converting enzyme (ACE) inhibitor for the treatment of hypertension, congestive heart failure following myocardial infarction and nephropathy.

Its use has increased widely since the initial publication in 2000 of the HOPE (Heart Outcomes Prevention Evaluation) study showed it to be effective in reducing the incidence of stroke, myocardial infarction and cardiovascular-related death in high-risk patients.

The results of an extension to the HOPE study, HOPE-TOO, published in the journal Circulation in September 2005, demonstrated sustained vascular and metabolic benefits obtained from treatment with Tritace® 10 mg.

Tritace® in 2005 figured among the market leaders in Canada, France and Spain and ranked no. 1 in Italy. Although its market exclusivity expired in Germany in January 2004, Tritace® (marketed as Delix®) remains the market leader in its class, with demand continuing to grow. Marketing rights in the United States were sold to King Pharmaceuticals in 1998. (Source: IMS end 2005, except GERS for France. ACE Inhibitors).